Pharmaceutical

ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

ADRX-0706 is under clinical development by Adcentrx Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Dec 26, 2023 - 18:00
ADRX-0706 is under clinical development by Adcentrx Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Read the original article

Tags:

Previous Article

GS-4528 by Gilead Sciences for Metastatic Renal Cell Carcinoma: Likelihood of Ap...

Next Article

AZD-9550 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Phase I/II trial begins for SpyGlass intraocular drug delivery implant

Phase I/II trial begins for SpyGlass intraocular drug d...

Oct 31, 2023

Empress Therapeutics emerges with $50m to fund small molecule development

Empress Therapeutics emerges with $50m to fund small mo...

Jun 21, 2023

AstraZeneca announces GLP-1 combo to treat obesity and co-morbidities

AstraZeneca announces GLP-1 combo to treat obesity and ...

Nov 14, 2023